Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc (“Jazz Pharmaceuticals” or the “Company”) (NASDAQ:JAZZ) concerning possible violations of federal securities laws.

On May 6, 2016, Jazz Pharmaceuticals acknowledged receipt of a subpoena from the U.S. Attorney’s Office for the District of Massachusetts in May 2016. According to the Company, the subpoena requested documents related to the Company’s “support of 501(c)(3) organizations that provide financial assistance to Medicare patients, and, for Xyrem, documents concerning our provision of financial assistance to Medicare patients.” Then on May 27, 2016, Bloomberg reported that Jazz Pharmaceuticals is one of three major drugmakers to disclose receipt of a subpoena as part of this expanding federal investigation. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/jazz-pharmaceuticals-jazz

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLPEduard Korsinsky, Esq., 212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com

Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Jazz Pharmaceuticals Charts.
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Jazz Pharmaceuticals Charts.